PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8819248-1	1996	We have previously shown that tight metabolic control by insulin therapy reduced thromboxane-dependent platelet activation in non-insulin-dependent diabetes mellitus (NIDDM) patients.	Thromboxanes	81-92	insulin	Homo sapiens	57-64	
24161392-5	2013	Although U46619 did not alter coronary artery smooth muscle cell proliferation, this thromboxane mimetic enhanced the proliferation induced by serum, insulin and growth factors, which was significantly inhibited by EV-077.	Thromboxanes	85-96	insulin	Homo sapiens	150-157	
10971087-2	2000	METHOD: The vasoactive substances prostacyclin and thromboxane, cyclic guanosine monophosphate, which can reflect the systemic NO production, serotonin, relaxin, insulin and melatonin were measured in nocturnal 8-hour urine before and after 2 and 4 weeks" estradiol treatment.	Thromboxanes	51-62	insulin	Homo sapiens	162-169	
1952228-1	1991	The use of glucose-insulin mixture (0.5 g/(kg.h) glucose and 1 U/(kg.h) insulin) during preperfusion period in 26 cardiosurgical patients subject to cardiopulmonary bypass surgery prevented the disturbances in carbohydrate metabolism, reduced hemoglobin glycosylation, and normalized thromboxane-prostacyclin system functions, as compared to the data obtained in control groups.	Thromboxanes	284-295	insulin	Homo sapiens	19-26	
6990716-0	1980	Effects of prostaglandins H2, D2, I2, and thromboxane on in vitro secretion of glucagon and insulin.	Thromboxanes	42-53	insulin	Homo sapiens	92-99	
2503285-2	1989	Insulin antibodies, through the formation of insulin anti-insulin platelet-fixing immune complexes, seem to increase the levels of platelet associated IgG and both insulin immunity and increased platelet associated IgG are associated with the highest degree of platelet aggregation and thromboxane synthesis.	Thromboxanes	286-297	insulin	Homo sapiens	0-7	
2503285-2	1989	Insulin antibodies, through the formation of insulin anti-insulin platelet-fixing immune complexes, seem to increase the levels of platelet associated IgG and both insulin immunity and increased platelet associated IgG are associated with the highest degree of platelet aggregation and thromboxane synthesis.	Thromboxanes	286-297	insulin	Homo sapiens	45-52	
2503285-2	1989	Insulin antibodies, through the formation of insulin anti-insulin platelet-fixing immune complexes, seem to increase the levels of platelet associated IgG and both insulin immunity and increased platelet associated IgG are associated with the highest degree of platelet aggregation and thromboxane synthesis.	Thromboxanes	286-297	insulin	Homo sapiens	58-65	
2503285-2	1989	Insulin antibodies, through the formation of insulin anti-insulin platelet-fixing immune complexes, seem to increase the levels of platelet associated IgG and both insulin immunity and increased platelet associated IgG are associated with the highest degree of platelet aggregation and thromboxane synthesis.	Thromboxanes	286-297	insulin	Homo sapiens	58-65	
3856894-11	1985	Thromboxane synthesizing activities in 6 patients treated by insulin decreased significantly during treatment (3.16 +/- 0.17 to 2.49 +/- 0.22 microgram .	Thromboxanes	0-11	insulin	Homo sapiens	61-68	
3856894-14	1985	These results suggest that the increased thromboxane synthesizing enzyme system is involved in the abnormal platelet function in diabetes independently of diabetic retinopathy, and that appropriate metabolic control using insulin might be successful in lowering the increased thromboxane synthesizing activity.	Thromboxanes	41-52	insulin	Homo sapiens	222-229	
3856894-14	1985	These results suggest that the increased thromboxane synthesizing enzyme system is involved in the abnormal platelet function in diabetes independently of diabetic retinopathy, and that appropriate metabolic control using insulin might be successful in lowering the increased thromboxane synthesizing activity.	Thromboxanes	276-287	insulin	Homo sapiens	222-229	
2838353-7	1988	Our study rules out the possibility that insulin reduces platelet-function-modifying intraplatelet cAMP levels or thromboxane A2 production, because this hormone decreases the platelet concentrations of cAMP--a phenomenon that, per se, promotes platelet aggregation--and does not modify collagen or Na+ arachidonate--induced platelet production of thromboxane A2, measured by radioimmunoassay of its stable-metabolite thromboxane B2.	Thromboxanes	114-125	insulin	Homo sapiens	41-48	
6762683-6	1982	The effect on thromboxane production might be related to normalization of plasma lipids which occurs with continuous infusion insulin therapy.	Thromboxanes	14-25	insulin	Homo sapiens	126-133